Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Balduzzi

Allergy Stockton, CA Medical Doctor

NPI 1235405952 CMS profile 8800392

4628 Georgetown Pl, Stockton, CA 95207

Open in the dashboard

General payments

$6,483

316 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Balduzzi of Stockton, CA is reported in the CMS Open Payments database as having received $6,483 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,485 71
2024 General $946 50
2023 General $1,766 93
2022 General $1,428 72
2021 General $651 28
2020 General $208 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Balduzzi
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Jeffrey Balduzzi were reported at $1,485. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Jeffrey Balduzzi Allergy median Middle half National median
2019 $0 $506 $151–$1,337 $163
2020 $208 $409 $108–$1,162 $114
2021 $651 $549 $125–$1,485 $132
2022 $1,428 $666 $161–$1,594 $149
2023 $1,766 $780 $186–$1,916 $160
2024 $946 $1,031 $271–$2,196 $164
2025 $1,485 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $879 22 payments
  2. Genzyme Corporation $763 44 payments
  3. Regeneron Healthcare Solutions, Inc. $740 27 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $578 28 payments
  5. GlaxoSmithKline, LLC. $436 36 payments
  6. CSL Behring $429 26 payments
  7. Amgen Inc. $423 24 payments
  8. Grifols USA, LLC $378 17 payments
  9. Pfizer Inc. $268 17 payments
  10. BioCryst US Sales Co., LLC $230 12 payments
  11. Other $1,360 63 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,422 311 payments
  2. Education $62 5 payments
Products named General payments · program years 2020–2025
  1. DUPIXENT Immunology $1,061 66 payments
  2. DUPIXENT Inflammation And Immunology $536 20 payments
  3. TEZSPIRE Respiratory $468 9 payments
  4. FASENRA $452 12 payments
  5. TEZSPIRE Inflammation $382 21 payments
  6. TAKHZYRO $337 14 payments
  7. NUCALA $255 25 payments
  8. Xembify $233 11 payments
  9. Haegarda $231 15 payments
  10. Orladeyo $230 12 payments
  11. Other $3,285 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$202,903

Medicare's payments for the services billed

Medicare patients

254

Average age 71

Services billed

13,237

175 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 50%
Diabetes 32%
COPD 24%
Ischemic heart disease 23%
Chronic kidney disease 23%
Depression 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $178
  • Regeneron Healthcare Solutions, Inc. $112
$290 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $79
  • Amgen Inc. $57
$136 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $87
$87 — —
Haegarda
  • CSL Behring $74
$74 — —
Hizentra
  • CSL Behring $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record